Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mirati’s Krazati Is Second KRAS Inhibitor To Market, But At Higher Price

Confirmatory Trial Seeks To Show Survival Advantage

Executive Summary

Krazati was approved for second-line NSCLC with labeling that positions it ahead of Lumakras on efficacy, but not safety. Pricing is slightly higher than for Amgen’s drug.

You may also be interested in...



Five Late-Breakers To Look Out For At ESMO

The upcoming European Society for Medical Oncology meeting in Madrid has a full slate of potentially practice-changing late-breaking clinical trials ready to be presented. Here, Scrip takes a look at five of the most eagerly anticipated.

Daiichi Sankyo Comes Out Swinging At WCLC As ADCs Steal Show

The Japanese drug maker gave multiple presentations on AstraZeneca-partnered Enhertu and other deruxtecan-based ADCs. Plus Gilead presented data on Trodelvy, Amgen showed early frontline data for Lumakras, and J&J’s EGFR-directed bispecific Rybrevant showed a 50% ORR in heavily pretreated patients.

Roche’s Divarasib Shows Competitive Data As Monotherapy In KRAS

A Phase I study showed better response and survival rates than Amgen’s Lumakras and Mirati’s Krazati, but investigators said confirmation from larger trials is needed.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147525

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel